Kerendia Dosage
Generic name: FINERENONE 10mg
Dosage form: tablet, film coated
Drug class: Aldosterone receptor antagonists
Medically reviewed by Drugs.com. Last updated on Aug 22, 2024.
Prior to Initiation of Kerendia
Measure serum potassium levels and estimated glomerular filtration rate (eGFR) before initiation. Do not initiate treatment if serum potassium is > 5.0 mEq/L.
Recommended Starting Dosage
The recommended starting dose of Kerendia is based on eGFR and is presented in Table 1.
eGFR (mL/min/1.73m2) |
Starting Dose |
≥ 60 |
20 mg once daily |
≥ 25 to < 60 |
10 mg once daily |
< 25 |
Initiation is not Recommended |
For patients who are unable to swallow whole tablets, Kerendia may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally.
Monitoring and Dose Adjustment
The target daily dose of Kerendia is 20 mg.
Measure serum potassium 4 weeks after initiating treatment and adjust dose (see Table 2); if serum potassium levels are > 4.8 to 5.0 mEq/L, initiation of Kerendia treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels. Monitor serum potassium 4 weeks after a dose adjustment and throughout treatment, and adjust the dose as needed (see Table 2).
Current Kerendia Dose |
|||
10 mg once daily |
20 mg once daily |
||
Current Serum Potassium (mEq/L) |
≤ 4.8 |
Increase the dose to 20 mg once daily.* |
Maintain 20 mg once daily. |
> 4.8 – 5.5 |
Maintain 10 mg once daily. |
Maintain 20 mg once daily. |
|
> 5.5 |
Withhold Kerendia. Consider restarting at 10 mg once daily when serum potassium ≤ 5.0 mEq/L. |
Withhold Kerendia. Restart at 10 mg once daily when serum potassium ≤ 5.0 mEq/L. |
* If eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose.
Frequently asked questions
More about Kerendia (finerenone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: aldosterone receptor antagonists
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.